Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study

被引：0
|
作者：
C Hanotin
F Thomas
SP Jones
E Leutenegger
P Drouin
机构：
[1] Laboratoires Knoll France,Department of Clinical Research
[2] Knoll Pharmaceuticals,Department of Clinical Research
[3] Service de Diabétologie,undefined
[4] Maladies Métaboliques et Nutrition,undefined
[5] CHU de Nancy,undefined
[6] Hôpital Jeanne d'Arc,undefined
来源：
International Journal of Obesity | 1998年 / 22卷
关键词：
obesity; weight loss; sibutramine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
OBJECTIVES: To assess the weight-reducing effects and tolerability of 5 mg, 10 mg and 15 mg daily doses of sibutramine, a novel serotonin and noradrenaline reuptake inhibitor (SNRI).
引用
收藏
页码：32 / 38
页数：6
相关论文
共 50 条
  • [41] The Relationship of Tofacitinib Plasma Concentration to Clinical Efficacy in Ulcerative Colitis Patients in a Dose-Ranging Phase 2 Study
    Mukherjee, Arnab
    Ito, Kaori
    Smith, Mike K.
    Su, Chinyu
    Niezychowski, Wojciech
    GASTROENTEROLOGY, 2014, 146 (05) : S367 - S368
  • [42] THE EFFECTS OF FENDOSAL, ASPIRIN AND PLACEBO ON POSTOPERATIVE DENTAL PAIN A DOSE-RANGING AND EFFICACY STUDY
    DESJARDINS, PJ
    COOPER, SA
    RUDERMAN, CM
    GALLEGOS, LT
    REYNOLDS, DC
    KRUGER, GO
    PHARMACOTHERAPY, 1983, 3 (01): : 52 - 57
  • [43] FLECAINIDE ACETATE, A NEW ANTI-ARRHYTHMIC AGENT - DOSE-RANGING AND EFFICACY STUDY
    HODGES, M
    HAUGLAND, JM
    GRANRUD, G
    ASINGER, RW
    MIKELL, FL
    KREJCI, J
    AMERICAN JOURNAL OF CARDIOLOGY, 1981, 47 (02): : 482 - 482
  • [44] A randomized, placebo-controlled, dose-ranging study to deltermine the efficacy, safety, and tolerability of perampanel, a selective amPA receptor antagonist, in patients with advanced Parkinson's disease
    Oertel, Wolfgang
    Eggert, Karla
    Squillacote, David
    NEUROLOGY, 2008, 70 (11) : A423 - A424
  • [45] Efficacy, Safety, and Tolerability of Pridopidine in Huntington's disease (HD): Results From the Phase II Dose-Ranging Study, Pride-HD
    Reilmann, R.
    McGarry, A.
    Landwehrmeyer, G.
    Kieburtz, K.
    Grachev, I.
    Eyal, E.
    Savola, J.
    Borowsky, B.
    Papapetropoulos, S.
    Hayden, M.
    MOVEMENT DISORDERS, 2017, 32
  • [46] A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder
    Sayed, Sehrish
    Van Dam, Nicholas T.
    Horn, Sarah R.
    Kautz, Marin M.
    Parides, Michael
    Costi, Sara
    Collins, Katherine A.
    Iacoviello, Brian
    Iosifescu, Dan V.
    Mathe, Aleksander A.
    Southwick, Steven M.
    Feder, Adriana
    Charney, Dennis S.
    Murrough, James W.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2018, 21 (01): : 3 - 11
  • [47] Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer
    Briasoulis, Evangelos
    Pappas, Periklis
    Puozzo, Christian
    Tolis, Christos
    Fountzilas, George
    Dafni, Urania
    Marselos, Marios
    Pavlidis, Nicholas
    CLINICAL CANCER RESEARCH, 2009, 15 (20) : 6454 - 6461
  • [48] Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study
    Atar, D.
    Malinin, A. I.
    Van Zyl, L.
    Lesperance, F.
    Frasure-Smith, N.
    Serebruany, V. L.
    EUROPEAN HEART JOURNAL, 2007, 28 : 336 - 336
  • [49] LOPRAZOLAM (DORMONOCT) - A MULTICENTER DOSE-RANGING STUDY IN GENERAL MEDICAL AND PREOPERATIVE PATIENTS
    FISCHER, HBJ
    MIDDLETON, RSW
    MAHMOUD, OMM
    PINES, A
    ANKIER, SI
    CLINICAL TRIALS JOURNAL, 1984, 21 (02) : 109 - 120
  • [50] A 1-WEEK DOSE-RANGING STUDY OF INHALED SALMETEROL IN PATIENTS WITH ASTHMA
    BRONSKY, EA
    KEMP, JP
    ORGEL, HA
    BIERMAN, CW
    TINKELMAN, DG
    VANAS, A
    LIDDLE, RF
    CHEST, 1994, 105 (04) : 1032 - 1037
12345